ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
about
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive LifeImplications of telomeres and telomerase in endometrial pathologyClear cell carcinoma arising in previous episiotomy scar: a case report and review of the literatureEstrogen signaling in the proliferative endometrium: implications in endometriosisSynthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersARID1A Is Essential for Endometrial Function during Early PregnancyEstablishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.ARID1A Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian CancerUpdate on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Influence of adriamycin on changes in Nanog, Oct-4, Sox2, ARID1 and Wnt5b expression in liver cancer stem cellsReliable in vitro studies require appropriate ovarian cancer cell linesLoss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibitionMechanisms by which SMARCB1 loss drives rhabdoid tumor growth.Novel biomarker candidates for the diagnosis of ovarian clear cell carcinomaTracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patientsOvarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?Stromal cells of endometrial carcinoma promotes proliferation of epithelial cells through the HGF/c-Met/Akt signaling pathway.Tumor Characteristics and Survival Outcome of Endometrial Cancer Arising in Adenomyosis: An Exploratory Analysis.AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.Expression of PIK3IP1 in the murine uterus during early pregnancy.Aberrant Akt Activation During Implantation Window in Infertile Women With Intramural Uterine Fibroids.SNF5 as a prognostic factor in skull base chordoma.Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development.Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell.PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.Periostin Enhances Migration, Invasion, and Adhesion of Human Endometrial Stromal Cells Through Integrin-Linked Kinase 1/Akt Signaling Pathway.Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro.TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations
P2860
Q26785614-D477481D-BBBB-4D27-AF11-205257A04C5DQ28066490-B5D0B3DE-54D0-4B32-8EE0-12BB6BB71082Q28072362-BCC4C79D-B3B3-4845-BC24-B3EB55733D39Q28079639-4D6E5547-018C-45AE-8FF5-002DF2D6A07DQ28257103-97A6D6F9-F13A-4791-BEDA-713330E66054Q30370823-245C64DE-93D4-4849-A224-47AB956FC33FQ33362731-34B63677-5E3A-4691-93FD-F8ED4BAC3BD8Q33583830-3F3A3FF3-5B9A-4E45-82A2-CCFD00AE9374Q33735170-78A82BF9-BDA5-45FC-8DD0-41A635986296Q33735351-BED12AD2-F8F7-4DCC-9FD1-3EF4389FEF7CQ33759421-AD2E8433-F295-4BEF-8819-EB41EAFB7541Q34221658-1CE5FEF1-7D02-4C31-B344-7EC3C070F8A7Q34332647-DC0DCF88-CED0-4B92-ACA1-5A29042E3BC3Q35871283-6DFE7B84-167A-44E2-8CF0-3B97EBFB2F98Q36254394-28D82421-6A7A-411A-9309-49DDBF5B8481Q36361630-E7F94332-D5DD-4C00-82EC-15FAB150C9A4Q36469778-1361FB9E-9F8A-4B8A-AEDF-3D10A991FC22Q36629514-E4F941EB-288D-4AB5-9311-93056AA695ACQ37109765-F5E2CFFA-A804-493C-B076-1C09236B0F88Q37438404-04CD90BD-0052-40DF-8D36-08AED10EAE4DQ37625908-B7E15A5C-CEE5-44BF-A486-AD80E654ECE3Q38899337-384DC733-A3DB-4644-8CFD-56B71AC665B2Q41145384-CFBBD814-D426-46B4-B328-B6BE52A9DA22Q41545361-AD8F6AAA-A424-408C-AF58-E8855519C0C3Q47242595-0FFCF61E-80DD-4FAF-B55C-5D68F625A8A0Q47429367-8BF0A2B8-7E9F-4EAC-8F68-6C9CD377976FQ47925228-59F8E847-33CF-431A-8583-16B9315D2566Q49884536-8BB31118-FFB9-450A-A882-48E7DF711664Q50073141-6B6768F1-3012-4C9F-A595-12237C0A8EDFQ52431428-E35E015C-7461-46A6-BFBD-4443F7185D86Q53529807-25DDFC80-4F95-4E33-BE41-84DA1F6225D9Q54285345-A3C8C9D6-F958-4377-8A3A-2B6B2F989D37Q55231951-96259CBF-5619-41C5-8593-86121EF3166DQ58604367-C016ACEE-FD6F-4DC0-8A69-50C6DF8A3C08
P2860
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@en
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@nl
type
label
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@en
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@nl
prefLabel
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@en
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@nl
P2093
P2860
P921
P356
P1476
ARID1A mutations and PI3K/AKT ...... associated ovarian carcinomas.
@en
P2093
Daniel Fink
Eleftherios P Samartzis
Konstantin J Dedes
Patrick Imesch
P2860
P304
18824-18849
P356
10.3390/IJMS140918824
P407
P5008
P577
2013-09-12T00:00:00Z